Skip to content
Open access

Cornea-Penetrating Nanodrug Co-Delivering VEGF-Silencing siRNA and Lutein for Treating Age-Related Macular Degeneration.

Sep 2026 · Advances in Materials · pp. e74994 · 0 citations · 37 references
Medicine

TL;DR

A noninvasive, cornea-penetrating nanodrug based on chitosan-modified lipid-polymer hybrid nanoparticles (LPNPs) for co-delivery of lutein and VEGF-silencing siRNA (Chi@Lu/si NPs) to treat AMD, which interrupts the pathological cycle driving CNV progression.

Abstract

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness among the elderly, driven by oxidative stress, chronic inflammation, and pathological choroidal neovascularization (CNV). Although intravitreal anti-vascular endothelial growth factor (VEGF) therapies remain the current clinical standard, their invasive nature and requirement for long-term repeated injections present substantial risks and patient burden, underscoring an urgent need for noninvasive therapeutic alternatives. Here, we develop a noninvasive, cornea-penetrating nanodrug based on chitosan-modified lipid-polymer hybrid nanoparticles (LPNPs) for co-delivery of lutein and VEGF-silencing siRNA (Chi@Lu/si NPs) to treat AMD. The structurally stabilized nanoparticles overcome the intrinsic instability of siRNA and the poor solubility of lutein, while the chitosan coating confers strong mucoadhesion and transient modulation of epithelial tight junctions, enabling a 3.3-fold enhancement in trans-epithelial transport across the ocular surface. Once delivered to the posterior segment, lutein effectively scavenges excessive reactive oxygen species and suppresses inflammatory cascades, whereas siRNA-VEGF achieves precise VEGF gene silencing, collectively interrupting the pathological cycle driving CNV progression. In a laser-induced CNV mouse model, topical administration of Chi@Lu/si NPs twice daily exerted potent inhibitory effects on neovascularization, with therapeutic efficacy comparable to that of intravitreal bevacizumab, reducing CNV lesion thickness to 58.9% of pre-treatment levels while maintaining excellent ocular biocompatibility.

Read PDF

Similar papers

Open access Aug 2026

Delivery of Anti-VEGFA Antibody by Plant-Derived Exosome-like Nanovesicles Alleviates Corneal Angiogenesis and Fibrosis via Topical Ocular Administration

Background: Pathological angiogenesis and stromal fibrosis after ocular chemical injury are primary drivers of corneal opacification and permanent vision loss. Topical administration of anti-VEGFA antibody is hampered by rapid tear clearance and poor penetration across the corneal epithelial barrier, resulting in insuf...

Xuan Chen, Qian Li, Hong-Ping Cui · 0 citations
Oct 2026

Mucoadhesive and ROS-responsive polymeric vesicles for anti-angiogenic therapy in corneal neovascularization.

Corneal neovascularization (CNV) is a major cause of visual impairment worldwide and results from disruption of the cornea's angiogenic privilege by excessive angiogenic signaling and oxidative stress. Current clinical management relies on corticosteroids, nonsteroidal anti-inflammatory drugs, or anti-VEGF injections,...

Yong-Liang Duan, Yi-Xin Chen, Xin Wang et al. · 0 citations
Open access Sep 2026

Intravitreal curcumin-loaded nanostructured lipid carriers for the management of post-traumatic proliferative vitreoretinopathy: optimization, in vitro characterization, and in vivo animal study.

Proliferative vitreoretinopathy (PVR) is a pathological vision-threatening complication that develops after a penetrating ocular trauma, retinal detachment and/or retinal reattachment surgery. After retinal break, epidermal growth factor (EGF) mediates the proliferation and dedifferentiation of retinal pigment epitheli...

G. Elattar, Mohammed Ahmed Hamdy Abdelhakiem, Noha A. Aboulhagag et al. · 0 citations
Review Open access Aug 2026

Liposomal Drug Delivery in Ocular Therapy: Strategies for Enhancing Corneal Penetration and Bioavailability

This review critically examines numerous surface-modification strategies applied to liposomal carriers to enhance corneal permeation and ocular bioavailability of drugs and highlights the advantages and disadvantages of each modification strategy, as well as the convergent mechanism of liposomal surface modification in...

Palak Mehta, Erik Moore, Alekha K. Dash et al. · 0 citations
Open access Sep 2026

Evaluation of collagen-derived peptide (EB-203) for treating neovascular age-related macular degeneration

Neovascular age-related macular degeneration has been one of the challenging ocular diseases due to severe ocular implications like vision loss. As a key protein factor, VEGF has been reported to be closely related to choroidal neovascularization (CNV) as a representative pathogenesis of neovascular AMD. Conventional...

Byul-Nim Ahn, K. Min, Jaewook Yang · 0 citations
Review Sep 2026

Targeting the choroidal neovascularization microenvironment: new perspectives in nanotherapeutic strategies.

An in-depth exploration of advanced nano-therapeutic strategies designed to multi-target angiogenic pathways, dynamically manipulate reactive oxygen species, disrupt hypoxia-driven feedback loops, reprogram the immunoinflammatory network, and restore defective cellular autophagy are provided.

Xiao-Yan Lu, Bo Li, Bao-Yuan Sun et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.